Cord blood/bone marrow stem cell therapy-heart disease - Gamida Cell

Drug Profile

Cord blood/bone marrow stem cell therapy-heart disease - Gamida Cell

Alternative Names: CardioCure; Cord blood stem cell therapy-myocardial infarction - Gamida-Cell; EE-AC133+; GC 011

Latest Information Update: 12 Dec 2013

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Gamida-Cell
  • Class
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Myocardial infarction

Most Recent Events

  • 31 Dec 2011 No development reported - Preclinical for Myocardial infarction in Israel (unspecified route)
  • 08 Jan 2007 Data presented at the 48th Annual Meeting and Exposition of the American Society of Hematology (ASH-2006) added to the Ischaemic Heart Disease pharmacodynamics section
  • 15 Nov 2006 Preclinical development of the cardiac regeneration product is ongoing
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top